-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $589

Benzinga·07/31/2025 16:04:06
Listen to the news
RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $640 to $589.